Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NT219 |
Synonyms | |
Therapy Description |
NT219 is a small molecule that inhibits both Stat3 and Irs1/2, resulting in decreased Stat3 phosphorylation and increased degradation of Irs1/2, and potentially leading to tumor growth inhibition (Cancer Res 2020;80(16 Suppl):Abstract nr 5639). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NT219 | NT-219|NT 219 | STAT3 Inhibitor 26 | NT219 is a small molecule that inhibits both Stat3 and Irs1/2, resulting in decreased Stat3 phosphorylation and increased degradation of Irs1/2, and potentially leading to tumor growth inhibition (Cancer Res 2020;80(16 Suppl):Abstract nr 5639). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04474470 | Phase Ib/II | Cetuximab + NT219 NT219 | A Study to Evaluate NT219 Alone and in Combination With ERBITUX (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer | Completed | USA | ISR | 0 |